Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.55 |
| ▸ | ADA | P00813 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | PGK2 | P07205 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15763428 | 1.00 | ADORA2A (0.55) | ADORA2AADAADORA2BCYP2C19ADORA3 | |
| SCHEMBL13468485 | 0.91 | ADORA2A (0.54) | ADORA2AADAADORA2BCYP2C19ADORA3 | |
| SCHEMBL15763449 | 0.91 | ADORA2A (0.54) | ADORA2AADAADORA2BCYP2C19ADORA3 | |
| SCHEMBL15888819 | 0.90 | ADORA2A (0.53) | ADORA2AADAADORA2BCYP2C19ADORA3 | |
| Beta-2'-C-Methyl-6-O-Methyl Guanosine SCHEMBL15628197 | 0.89 | ADORA2A (0.66) | ADORA2AADAADORA2BCYP2C19ADORA3 | |
| Beta-2'-C-Methyl-6-O-Methyl Guanosine SCHEMBL12219172 | 0.89 | ADORA2A (0.66) | ADORA2AADAADORA2BCYP2C19ADORA3 | |
| Beta-2'-C-Methyl-6-O-Methyl Guanosine SCHEMBL721333 | 0.89 | ADORA2A (0.66) | ADORA2AADAADORA2BCYP2C19ADORA3 | |
| Beta-2'-C-Methyl-6-O-Methyl Guanosine SCHEMBL14816756 | 0.89 | ADORA2A (0.66) | ADORA2AADAADORA2BCYP2C19ADORA3 | |
| Beta-2'-C-Methyl-6-O-Methyl Guanosine SCHEMBL12939406 | 0.89 | ADORA2A (0.66) | ADORA2AADAADORA2BCYP2C19ADORA3 | |
| Beta-2'-C-Methyl-6-O-Methyl Guanosine SCHEMBL12194676 | 0.89 | ADORA2A (0.66) | ADORA2AADAADORA2BCYP2C19ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061041-B2 | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-06-05 | — | — | US | disclosed |
| WO-2012142085-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SLC29A2, SLC29A1, SLC28A2 | ADORA2A 24/4885ADA 19/4885ADORA2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.